News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 27, 2015, 17:50 ET
Amgen Logo.

FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)

 Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new cholesterol-lowering medication,...

Aug 25, 2015, 09:15 ET
Amgen Logo.

Amgen To Present New Long-Term Repatha™ (Evolocumab) Data Analysis At ESC Congress 2015

Amgen (NASDAQ:AMGN) today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of...

Aug 25, 2015, 09:00 ET
Amgen Logo.

Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)

Amgen (NASDAQ: AMGN) today announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for...

Aug 18, 2015, 09:00 ET
Amgen Logo.

Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs

 Amgen (NASDAQ:AMGN) and the Center for Social Sector Leadership at the University of California (UC), Berkeley's Haas School of Business today...

Jul 30, 2015, 16:05 ET
Amgen Logo.

Amgen Announces Appointment Of Fred Hassan To Board Of Directors

 Amgen (NASDAQ: AMGN) today announced the appointment of Fred Hassan, partner and managing director of Warburg Pincus LLC, to the Amgen Board...

Jul 30, 2015, 16:01 ET
Amgen Logo.

Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57

 Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2015. Key results include: - Total revenues increased 4...

Jul 28, 2015, 17:46 ET
Amgen Logo.

Amgen Announces 2015 Third Quarter Dividend

Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the third quarter of 2015. The dividend...

Jul 27, 2015, 17:10 ET
Amgen Logo. (PRNewsFoto/Amgen)

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha(TM) (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

 Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Repatha™ (evolocumab), the...

Jul 27, 2015, 16:01 ET
Amgen Logo.

Amgen Announces Webcast of 2015 Second Quarter Financial Results

 Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of...

Jul 24, 2015, 12:40 ET
Amgen Logo.

FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

 Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for...

Jul 23, 2015, 09:00 ET
Amgen Logo.

Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma

 Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...

Jul 16, 2015, 16:01 ET
Amgen Logo.

Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

 Amgen (NASDAQ:AMGN) today announced the top-line results of a Phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy...

Jun 19, 2015, 16:00 ET
Amgen Logo.

Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine

Amgen (NASDAQ: AMGN) today announced positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled...

Jun 18, 2015, 16:01 ET
Amgen Logo.

Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care

 Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix® (panitumumab) and best supportive care (BSC) met its...

Jun 10, 2015, 08:00 ET
Amgen Logo.

Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol

 Amgen (NASDAQ: AMGN) today announced that the Company will discuss the data supporting the RepathaTM (evolocumab) Biologics License...

Jun 08, 2015, 16:00 ET
Amgen Logo.

Amgen To Present At The Goldman Sachs Global Healthcare Conference

 Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Global Healthcare Conference at 8:40 a.m. PT on Thursday, June 11, 2015, at the...

Jun 05, 2015, 08:00 ET
Amgen Logo.

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

 Amgen (NASDAQ: AMGN) today announced the completion of patient enrollment in the FOURIER outcomes trial designed to evaluate whether treatment...

Jun 02, 2015, 01:00 ET
Amgen Logo.

Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab

Amgen (NASDAQ: AMGN) today announced a collaboration with Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene...

Jun 01, 2015, 09:00 ET
Amgen Logo.

Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors

 Amgen (NASDAQ: AMGN) today announced results from a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating the...

May 31, 2015, 07:00 ET
Amgen Logo

Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma

 Amgen (NASDAQ:AMGN) today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®...